UNITED STATES

                     SECURITIES AND EXCHANGE COMMISSION

                          Washington, D. C.  20549


                                FORM 12b-25

                        NOTIFICATION OF LATE FILING

                                                    SEC FILE NUMBER 0-24480
                                                    CUSIP NUMBER 801006107

(Check One) [ ] Form 10-K   [ ] Form 20-F   [ ] Form 11-K   [X] Form 10-Q
[ ] Form N-SAR [ ] Form N-CSR

For the Period Ended March 31, 2004.

     [ ] Transition Report on Form 10-K
     [ ] Transition Report on Form 20-F
     [ ] Transition Report on Form 11-K
     [ ] Transition Report on Form 10-Q
     [ ] Transition Report on Form N-SAR

For the Transition Period Ended ________________

          Nothing in this form shall be construed to imply that the Commission
has verified any information contained herein.

          If the notification relates to a portion of the filing checked
above, identify the Item(s) to which the notification relates:

                 PART I - REGISTRANT INFORMATION

Full Name of Registrant:      SANGUINE CORPORATION

Former Name if Applicable:    N/A

Address of Principal          101 East Green Street, Suite #11
Executive Office:             Pasadena, California 91105

                PART II - RULES 12b-25 (b) and (c)

If the subject report could not be filed without unreasonable effort or
expense, and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed.  (Check box if appropriate) [X]

     (a)  The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;

     (b)  The subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof,
will be filed on or before the fifteenth calendar day following the prescribed
due date; or the subject quarterly report or transition report on Form 10-Q,
or portion thereof will be filed on or before the fifth calendar day following
the prescribed due date.

     (c)  The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.

                       PART III - NARRATIVE

          The Company changed accountants on December 11, 2003 and is in the
process of filing all reports for the past two years, including this 10QSB for
the quarter ended March 31, 2004.  We believe that the subject Quarterly
Report will be available for filing on or before May 22, 2004.

                   PART IV - OTHER INFORMATION

          (1)  Name and address of person to contact in regard to this
notification:

               Branden T. Burningham, Esq.
               455 East 500 South, Suite 205
               Salt Lake City, Utah  84111
               Telephone:  (801) 363-7411

          (2)  Have all other periodic reports required under Section 13 or
15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period
that the Registrant was required to file such report(s) been filed?  If the
answer is no, identify report(s).
                                             [ ] Yes  [X] No

Annual Reports for the years ended December 31, 2002 and 2003 and Quarterly
Reports for the quarters ended March 31, 2003, June 30, 2003 and September 30,
2003.

          (3)  Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or
portion thereof?
                                             [ ] Yes  [X] No

          If so, attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.

          SANGUINE CORPORATION has caused this notification to be signed on
its behalf by the undersigned hereunto duly authorized.

Date: 5/17/04                          By/s/Thomas C. Drees
      -------                             --------------------------
                                          Thomas C. Drees, Ph.D., MBA
                                          CEO, President and Chairman of the
                                          Board of Directors